Approval · Notice of Compliance 25516 · 2021

LIPRELOG: Notice of Compliance 25516

Issued March 22, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 25516
Date: March 22, 2021
Company: Eli Lilly Canada IncToronto, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Labelling Only
Reason: Additional product name

Products in this notice

Brand	DIN	Status today
LIPRELOG	02513331	Cancelled Pre Market
LIPRELOG	02513374	Cancelled Pre Market
LIPRELOG	02513366	Cancelled Pre Market
LIPRELOG	02513358	Cancelled Pre Market

Medicinal ingredients

INSULIN LISPRO 1,000 UNIT per 10ML
INSULIN LISPRO 300 UNIT per 3ML